Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? (Q36942143)
Jump to navigation
Jump to search
scientific article published on 21 May 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? |
scientific article published on 21 May 2013 |
Statements
1 reference
Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? (English)
1 reference
Eric P Brass
1 reference
21 May 2013
1 reference
1 reference
1823-1826
1 reference
Identifiers
1 reference
1 reference
1 reference